Log In
BCIQ
Print this Print this
 

miR-21 (anti-miR-21) (RG-012) (formerly antagomir-21)

  Manage Alerts
Collapse Summary General Information
Company Regulus Therapeutics Inc.
DescriptionAntisense oligonucleotide inhibiting microRNA-21 (miR-21)
Molecular Target MicroRNA-21 (miR-21)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$35.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/01/2013

Undisclosed

$35.0M

$120.0M

Get a free BioCentury trial today